Sagimet Biosciences Inc. (SGMT)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Sagimet Biosciences Inc. (SGMT) trades at $7.74 with AI Score 52/100 (Grade B). Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for diseases resulting from dysfunctional lipid metabolism pathways. Market cap: $252.18M, Sector: Healthcare.
Price live · AI analysis from May 10, 2026SGMT stock analysis for 2026: Analysts have set a consensus price target of $8.00 for Sagimet Biosciences Inc., suggesting 3.4% upside from the current price of $7.74. The AI MoonshotScore is 52/100, indicating a neutral outlook. Key factors: analyst coverage, AI-driven quantitative scoring.
SGMT: the 1 perspectives are evenly split.
How is this calculated? →Sagimet Biosciences Inc. (SGMT) Healthcare & Pipeline Overview
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in fatty acid synthase (FASN) inhibitors. Their lead drug candidate, Denifanstat, targets nonalcoholic steatohepatitis (NASH) and acne, positioning them in the high-growth metabolic disease and dermatology markets. TVB-3567 is being developed for various cancers.
What Is the Investment Thesis for SGMT?
Sagimet Biosciences Inc. presents a notable research candidate due to its focus on FASN inhibitors, particularly Denifanstat, targeting NASH and acne. NASH represents a multi-billion dollar market with limited approved therapies, offering significant upside potential for Denifanstat if clinical trials are successful. The company's pipeline also includes TVB-3567 for various cancers, providing additional diversification and potential value creation. Key catalysts include upcoming clinical trial results for Denifanstat in NASH, which could drive significant stock appreciation. However, the company faces risks associated with clinical trial outcomes, regulatory approvals, and competition from other companies developing NASH therapies. With a market cap of $252.18M and a beta of 3.21, Sagimet offers high-risk, high-reward potential for investors.
Based on FMP financials and quantitative analysis
SGMT Key Highlights
- Lead drug candidate Denifanstat targets the multi-billion dollar NASH market.
- TVB-3567 is being developed for various cancers, diversifying the pipeline.
- The company changed its name to Sagimet Biosciences Inc. in August 2019.
- Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.
- The company employs 14 people.
Who Are SGMT's Competitors?
SGMT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are SGMT's Key Strengths?
- Novel FASN inhibitor technology.
- Lead drug candidate targeting NASH, a large and growing market.
- Experienced management team.
- Pipeline diversification with TVB-3567 for cancer.
What Are SGMT's Weaknesses?
- Clinical-stage company with no approved products.
- Reliance on the success of Denifanstat and TVB-3567.
- Limited financial resources.
- Small number of employees.
What Could Drive SGMT Stock Higher?
- Clinical trial results for Denifanstat in NASH.
- Regulatory submissions for Denifanstat.
- Advancement of TVB-3567 through clinical development.
- Potential partnerships and collaborations.
What Are the Key Risks for SGMT?
- Negative return on equity (-37.6%) — the business is not currently generating profit on shareholder capital.
- Weak fundamentals — a Piotroski F-Score of 1/9 flags soft profitability, leverage or efficiency.
- Clinical trial failures.
- Regulatory delays or rejection.
- Competition from other companies developing NASH therapies.
- Patent expiration.
- Limited financial resources.
What Are the Growth Opportunities for SGMT?
- Denifanstat for NASH: The NASH market is projected to reach billions of dollars in the coming years, driven by the increasing prevalence of obesity and diabetes. Sagimet's Denifanstat has the potential to capture a significant share of this market if it demonstrates positive clinical trial results and receives regulatory approval. The timeline for potential commercialization is dependent on successful completion of ongoing clinical trials.
- Denifanstat for Acne: Sagimet is also developing Denifanstat for the treatment of acne. The acne market is a well-established market with a consistent demand. Positive clinical trial results in acne could provide another revenue stream for the company. The timeline for potential commercialization is dependent on successful completion of ongoing clinical trials.
- TVB-3567 for Cancer: Sagimet is developing TVB-3567 for various types of cancers. The oncology market is a large and growing market, with a constant need for new and effective therapies. Positive clinical trial results in cancer could provide another revenue stream for the company. The timeline for potential commercialization is dependent on successful completion of ongoing clinical trials.
- Partnerships and Collaborations: Sagimet could pursue partnerships and collaborations with larger pharmaceutical companies to accelerate the development and commercialization of its drug candidates. This could provide access to additional funding, expertise, and resources. The timing of any potential partnerships is uncertain.
- Expansion into New Indications: Sagimet could explore the potential of its FASN inhibitors in other diseases characterized by dysfunctional lipid metabolism pathways. This could expand the company's pipeline and create new growth opportunities. The timing of any potential expansion is uncertain.
What Opportunities Does SGMT Have?
- Positive clinical trial results for Denifanstat in NASH.
- Regulatory approval and commercialization of Denifanstat.
- Partnerships and collaborations with larger pharmaceutical companies.
- Expansion into new indications for FASN inhibitors.
What Threats Does SGMT Face?
- Clinical trial failures.
- Regulatory delays or rejection.
- Competition from other companies developing NASH therapies.
- Patent expiration.
What Are SGMT's Competitive Advantages?
- Proprietary FASN inhibitor technology.
- Patent protection for Denifanstat and TVB-3567.
- Clinical data supporting the safety and efficacy of its drug candidates.
- Expertise in lipid metabolism and drug development.
What Does SGMT Do?
Sagimet Biosciences Inc., formerly known as 3-V Biosciences, was founded in 2006 and is headquartered in San Mateo, California. The company is dedicated to developing novel therapeutics targeting dysfunctional lipid metabolism pathways. Their primary focus is on fatty acid synthase (FASN) inhibitors, a class of drugs with the potential to address a range of diseases, including nonalcoholic steatohepatitis (NASH), acne, and various cancers. Sagimet's lead drug candidate, Denifanstat, is currently in clinical development for NASH and acne. NASH is a significant unmet medical need, affecting millions worldwide and representing a substantial market opportunity. The company is also advancing TVB-3567, another FASN inhibitor, for the treatment of different types of cancers. Sagimet's pipeline reflects a strategic focus on areas with high unmet needs and significant commercial potential, leveraging its expertise in lipid metabolism and FASN inhibition to develop innovative therapies. The company changed its name to Sagimet Biosciences Inc. in August 2019, marking a new chapter in its evolution as a clinical-stage biopharmaceutical company.
What Products and Services Does SGMT Offer?
- Develops fatty acid synthase (FASN) inhibitors.
- Targets diseases resulting from dysfunctional lipid metabolism pathways.
- Lead drug candidate is Denifanstat.
- Denifanstat is being developed for nonalcoholic steatohepatitis (NASH).
- Denifanstat is also being developed for acne.
- TVB-3567 is being developed for various types of cancers.
How Does SGMT Make Money?
- Develops and patents novel therapeutics.
- Conducts clinical trials to demonstrate safety and efficacy.
- Seeks regulatory approval from agencies like the FDA.
- Commercializes approved drugs directly or through partnerships.
What Industry Does SGMT Operate In?
Sagimet Biosciences Inc. operates within the biotechnology industry, which is characterized by high R&D spending, long development timelines, and significant regulatory hurdles. The NASH market, which Sagimet is targeting with Denifanstat, is expected to grow rapidly in the coming years due to the increasing prevalence of obesity and related metabolic disorders. The competitive landscape includes established pharmaceutical companies and other biotech firms developing NASH therapies. Sagimet's success will depend on its ability to demonstrate the safety and efficacy of Denifanstat in clinical trials and secure regulatory approvals.
Who Are SGMT's Key Customers?
- Patients suffering from nonalcoholic steatohepatitis (NASH).
- Patients suffering from acne.
- Patients suffering from various types of cancers.
- Healthcare providers who prescribe Sagimet's drugs.
ROE -38%Key Financial Metrics
Return on equity for Sagimet Biosciences Inc. stands at -37.6%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -40.4%, showing how much profit it generates from its asset base. Its free cash flow yield is -16.3%, a gauge of the cash the business throws off relative to its market value. A current ratio of 20.34 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -17.9%, the inverse of the P/E and a quick read on earnings relative to price.
How Sagimet Biosciences Inc. Is Valued
Sagimet Biosciences Inc. carries a market capitalization of $252.18M, placing it in the micro-cap category. Relative to its peer group, SGMT's quantitative score of 52/100 is below the peer average of 76/100.
F-Score 1/9Financial Health
Sagimet Biosciences Inc.'s Piotroski F-Score is 1/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of 23.17 places it in the safe zone, indicating low near-term bankruptcy risk.
FY2026 estForward Outlook
Wall Street analysts project Sagimet Biosciences Inc. revenue of about $111K for fiscal 2026, with EPS near $-1.20. The estimate reflects 6 contributing analysts.
SGMT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's potential, indicating that key stakeholders believe in its future.
- Community sentiment has turned positive as discussions around the company's innovative treatments gain traction.
- Recent partnerships and collaborations have strengthened market perception, showcasing the company's commitment to growth and development.
- The overall biotech sector has seen increased interest, which could benefit Sagimet as investors look for promising opportunities.
Bear Case
- Concerns over regulatory hurdles in the biotech industry could impact the company's timelines and market entry.
- Social sentiment has shown some skepticism regarding the sustainability of recent stock price movements, leading to cautious investor behavior.
- Negative sentiment from analysts regarding the competitive landscape may deter new investors from entering the stock.
- Recent market volatility has led to a general risk-off approach, causing investors to shy away from smaller biotech firms like Sagimet.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
SGMT Latest News
SGMT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for SGMT.
Price Targets
Consensus target: $8.00
SGMT MoonshotScore
What does this score mean?
The MoonshotScore rates SGMT's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Latest Sagimet Biosciences Inc. Analysis
Leadership: David A. Happel
CEO
David A. Happel serves as the CEO of Sagimet Biosciences Inc. His background includes extensive experience in the biopharmaceutical industry, with a focus on drug development and commercialization. He has held leadership positions at various companies, contributing to the advancement of innovative therapies. His expertise spans strategic planning, clinical development, and business development, making him a valuable asset to Sagimet.
Track Record: Under David A. Happel's leadership, Sagimet Biosciences Inc. has focused on advancing its pipeline of FASN inhibitors, particularly Denifanstat, through clinical development. He has overseen the execution of clinical trials and the pursuit of regulatory approvals. His strategic decisions have shaped the company's direction and positioned it for potential success in the NASH and oncology markets.
What Investors Ask About Sagimet Biosciences Inc. (SGMT) — Healthcare
What does Sagimet Biosciences Inc. do?
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing therapeutics for diseases resulting from dysfunctional lipid metabolism pathways. Their lead drug candidate, Denifanstat, is a FASN inhibitor targeting nonalcoholic steatohepatitis (NASH) and acne. The company is also developing TVB-3567, a FASN inhibitor for various cancers. Sagimet's business model revolves around discovering, developing, and commercializing novel therapies in areas with high unmet medical needs.
What do analysts say about SGMT stock?
Analyst coverage of Sagimet Biosciences Inc. (SGMT) is still emerging, given its clinical-stage nature. Key valuation metrics will depend on the success of Denifanstat's clinical trials and potential regulatory approvals. Growth considerations center on the NASH market opportunity and the potential for TVB-3567 in oncology. Analyst consensus will likely be heavily influenced by clinical trial data and regulatory milestones. The beta is 3.21.
What are the main risks for SGMT?
The main risks for Sagimet Biosciences Inc. include clinical trial failures, regulatory delays or rejection, competition from other companies developing NASH therapies, and patent expiration. As a clinical-stage company, Sagimet is heavily reliant on the success of its drug candidates. Any setbacks in clinical development or regulatory approval could significantly impact the company's prospects. Competition in the NASH market is also intense, with numerous companies pursuing different therapeutic approaches.
What is Sagimet Biosciences Inc.'s drug pipeline status?
Sagimet Biosciences Inc.'s pipeline is focused on fatty acid synthase (FASN) inhibitors. The lead drug candidate, Denifanstat, is in clinical development for nonalcoholic steatohepatitis (NASH) and acne. TVB-3567 is being developed for various cancers. Upcoming catalysts include clinical trial results for Denifanstat in NASH and potential regulatory submissions. The pipeline reflects a strategic focus on areas with high unmet needs and significant commercial potential.
How does Sagimet Biosciences Inc. manage patent expiration risks?
Sagimet Biosciences Inc. manages patent expiration risks by actively seeking patent protection for its FASN inhibitors and related technologies. The company aims to build a strong intellectual property portfolio to protect its drug candidates from biosimilar competition. Lifecycle management strategies may include developing new formulations or indications for existing drugs to extend their market exclusivity. The company also monitors the competitive landscape and proactively addresses any potential patent challenges.
What are the key factors to evaluate for SGMT?
Sagimet Biosciences Inc. (SGMT) holds an AI score of 52/100 (moderate). Analysts target $8.00 (+3%). Not financial advice.
How frequently does SGMT data refresh on this page?
SGMT prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven SGMT's recent stock price performance?
Sagimet Biosciences Inc. (SGMT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Novel FASN inhibitor technology. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Clinical trial outcomes are inherently uncertain.